Amarin (AMRN) News Today $10.91 -0.07 (-0.64%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$10.90 -0.01 (-0.09%) As of 07:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Amarin (AMRN) Expected to Announce Earnings on WednesdayAmarin (NASDAQ:AMRN) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-7-amarin-co-plc-stock/)May 2 at 6:50 AM | marketbeat.comAmarin Corporation plc: Amarin Regains Compliance with Nasdaq Minimum Bid Price RequirementApril 30, 2025 | finanznachrichten.deAmarin Corporation plc to Host Conference Call for First Quarter 2025 Financial ResultsApril 30, 2025 | nasdaq.comAmarin Regains Compliance with Nasdaq Minimum Bid Price RequirementApril 29, 2025 | globenewswire.comZacks Research Has Bullish Estimate for Amarin Q1 EarningsApril 29, 2025 | americanbankingnews.comResearch Analysts Set Expectations for Amarin Q1 EarningsAmarin Co. plc (NASDAQ:AMRN - Free Report) - Zacks Research upped their Q1 2025 EPS estimates for shares of Amarin in a research note issued on Thursday, April 24th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn ($1.23) per share for the quarter, upApril 29, 2025 | marketbeat.comAmarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025April 28, 2025 | globenewswire.comAmarin Co. plc (NASDAQ:AMRN) Short Interest UpdateAmarin Co. plc (NASDAQ:AMRN - Get Free Report) was the recipient of a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 629,400 shares, a drop of 94.7% from the March 31st total of 11,970,000 shares. Based on an average trading volume of 88,700 shares, the days-to-cover ratio is currently 7.1 days. Approximately 3.1% of the company's shares are short sold.April 28, 2025 | marketbeat.comQ1 Earnings Forecast for Amarin Issued By Zacks ResearchAmarin Co. plc (NASDAQ:AMRN - Free Report) - Investment analysts at Zacks Research issued their Q1 2027 earnings per share estimates for shares of Amarin in a research note issued on Thursday, April 24th. Zacks Research analyst R. Department expects that the biopharmaceutical company will post eaApril 27, 2025 | marketbeat.comAmarin (NASDAQ:AMRN) Stock Crosses Above 200-Day Moving Average - Here's What HappenedAmarin (NASDAQ:AMRN) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell?April 27, 2025 | marketbeat.comTop 2 Health Care Stocks That May Crash This MonthApril 25, 2025 | benzinga.comStockNews.com Begins Coverage on Amarin (NASDAQ:AMRN)StockNews.com began coverage on Amarin in a report on Wednesday. They issued a "sell" rating on the stock.April 17, 2025 | marketbeat.comAmarin (NASDAQ:AMRN) Sees Unusually-High Trading Volume - Should You Buy?Amarin (NASDAQ:AMRN) Sees Strong Trading Volume - Here's What HappenedApril 16, 2025 | marketbeat.comAmarin (NASDAQ:AMRN) Sets New 12-Month Low - What's Next?Amarin (NASDAQ:AMRN) Reaches New 12-Month Low - What's Next?April 13, 2025 | marketbeat.comAmarin trading halted, news pendingApril 11, 2025 | markets.businessinsider.comAmarin confirms effective data for 1-for-20 ADS ratio changeApril 9, 2025 | markets.businessinsider.comAmarin Confirms Effective Date for 1-For-20 ADS Ratio ChangeApril 9, 2025 | globenewswire.comAmarin Confirms Effective Date for 1-For-20 ADS Ratio ChangeApril 9, 2025 | globenewswire.comAmarin Appoints JEC Capital Partners’ Michael Torok to Board of DirectorsApril 7, 2025 | finance.yahoo.comAmarin Appoints JEC Capital Partners' Michael Torok to Board of DirectorsApril 7, 2025 | globenewswire.comAmarin presents data at ACC.25 on EPA in lipoprotein-enriched plasmaApril 1, 2025 | markets.businessinsider.comAmarin (NASDAQ:AMRN) Earns Sell Rating from Analysts at StockNews.comStockNews.com assumed coverage on shares of Amarin in a report on Monday. They issued a "sell" rating for the company.March 31, 2025 | marketbeat.comAmarin Co. plc (NASDAQ:AMRN) Short Interest Down 35.4% in MarchAmarin Co. plc (NASDAQ:AMRN - Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 10,840,000 shares, a decrease of 35.4% from the February 28th total of 16,790,000 shares. Currently, 2.7% of the shares of the stock are sold short. Based on an average daily volume of 1,580,000 shares, the short-interest ratio is currently 6.9 days.March 30, 2025 | marketbeat.comAmarin Stock Set to Reverse Split on Friday, April 11th (NASDAQ:AMRN)Shares of Amarin Co. plc (NASDAQ:AMRN - Free Report) are set to reverse split on Friday, April 11th. The 1-20 reverse split was announced on Wednesday, March 12th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, April 10th.March 26, 2025 | marketbeat.comAmarin (NASDAQ:AMRN) Coverage Initiated by Analysts at StockNews.comStockNews.com initiated coverage on Amarin in a report on Sunday. They issued a "sell" rating for the company.March 23, 2025 | marketbeat.comAmarin shareholder group urges board to initiate strategic reviewMarch 21, 2025 | markets.businessinsider.comAmarin announces additional in vitro data with EPA to be presentedMarch 20, 2025 | markets.businessinsider.comAmarin gains amid shareholder group push for strategic reviewMarch 19, 2025 | seekingalpha.comConcerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of UnderperformanceMarch 19, 2025 | businesswire.comNew Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & ExpoMarch 19, 2025 | globenewswire.comAmarin (NASDAQ:AMRN) Cut to Sell at StockNews.comStockNews.com downgraded Amarin from a "hold" rating to a "sell" rating in a research note on Saturday.March 15, 2025 | marketbeat.comAmarin Corporation plc (NASDAQ:AMRN) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | msn.comAMRN's Q4 Earnings Lag Estimates, Stock Down on Ratio Change PlanMarch 13, 2025 | msn.comAmarin (NASDAQ:AMRN) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPSAmarin (NASDAQ:AMRN - Get Free Report) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). Amarin had a negative return on equity of 7.22% and a negative net margin of 16.33%.March 13, 2025 | marketbeat.comAmarin Corporation’s Earnings Call: A Mixed OutlookMarch 12, 2025 | tipranks.comAmarin Plc (AMRN) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | finance.yahoo.comAmarin Corporation plc: Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) ProgramMarch 12, 2025 | finanznachrichten.deAmarin reports Q4 adjusted EPS (2c) vs. 0c last yearMarch 12, 2025 | markets.businessinsider.comAmarin announce splan to initiate ratio change under ADR programMarch 12, 2025 | markets.businessinsider.comAmarin drops despite Q4 beat amid ADS ratio changeMarch 12, 2025 | msn.comAmarin Corporation plc (AMRN) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | seekingalpha.comAmarin expects cash to support continuing operations for ‘foreseeable future’March 12, 2025 | markets.businessinsider.comAmarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) ProgramMarch 12, 2025 | markets.businessinsider.comAmarin (NASDAQ:AMRN) Stock Rating Upgraded by StockNews.comStockNews.com raised shares of Amarin from a "sell" rating to a "hold" rating in a research note on Friday.March 8, 2025 | marketbeat.comAmarin (AMRN) Expected to Announce Quarterly Earnings on WednesdayAmarin (NASDAQ:AMRN) will be releasing earnings before the market opens on Wednesday, March 12, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=667912)March 5, 2025 | marketbeat.comAmarin’s vascepa shows cardiovascular efficacy in published trialFebruary 27, 2025 | markets.businessinsider.comAmarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol LoweringFebruary 27, 2025 | globenewswire.comAmarin (NASDAQ:AMRN) Stock Rating Lowered by StockNews.comStockNews.com downgraded shares of Amarin from a "hold" rating to a "sell" rating in a research note on Tuesday.February 26, 2025 | marketbeat.comAmarin receives national reimbursement for VAZKEPA in AustriaFebruary 26, 2025 | markets.businessinsider.comAmarin Receives National Reimbursement for VAZKEPA® in AustriaFebruary 25, 2025 | markets.businessinsider.com Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address AMRN Media Mentions By Week AMRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMRN News Sentiment▼0.530.73▲Average Medical News Sentiment AMRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMRN Articles This Week▼102▲AMRN Articles Average Week Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Avadel Pharmaceuticals News Vir Biotechnology News Anavex Life Sciences News Bicara Therapeutics News Chimerix News Avid Bioservices News Day One Biopharmaceuticals News Oculis News CureVac News AbCellera Biologics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMRN) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
